Abstract
Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I / B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N-(phenylalkyl)-N- (phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate.
Keywords: class, class III antiarrhythmics, dual mode of action, n-(phenylalkyl)-n-(phenoxyalkyl)amines, gykI 16638
Current Medicinal Chemistry
Title: Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action
Volume: 11 Issue: 1
Author(s): Peter Matyus, Ildiko Varga, Tivadar Rettegi, Antal Simay, Nikolett Kallay, Laszlo Karolyhazy, Akos Kocsis, Andras Varro, Istvan Penzes and Julius Gy. Papp
Affiliation:
Keywords: class, class III antiarrhythmics, dual mode of action, n-(phenylalkyl)-n-(phenoxyalkyl)amines, gykI 16638
Abstract: Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I / B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N-(phenylalkyl)-N- (phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate.
Export Options
About this article
Cite this article as:
Matyus Peter, Varga Ildiko, Rettegi Tivadar, Simay Antal, Kallay Nikolett, Karolyhazy Laszlo, Kocsis Akos, Varro Andras, Penzes Istvan and Papp Gy. Julius, Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action, Current Medicinal Chemistry 2004; 11 (1) . https://dx.doi.org/10.2174/0929867043456232
DOI https://dx.doi.org/10.2174/0929867043456232 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiac Mitochondrial Alterations Observed in Hyperglycaemic Rats - What Can We Learn From Cell Biology?
Current Diabetes Reviews Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Effect of Flaxseed on Blood Lipid Level in Hyperlipidemic Patients
Reviews on Recent Clinical Trials Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design Long-term Success and Follow-up After Atrial Fibrillation Ablation
Current Cardiology Reviews Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Central Blood Pressure in Chronic Kidney Disease: Latest Evidence and Clinical Relevance
Current Hypertension Reviews Attention Deficit Hyperactive Disorder and Occurrence of Tic Disorders in Children and Adolescents—What is the Verdict
Current Pediatric Reviews The Prevalence, Morbidities, and Treatments of Insomnia
CNS & Neurological Disorders - Drug Targets The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Treatment of Takotsubo Cardiomyopathy
Current Pharmaceutical Design A Guide to Treatment of Sarcoidosis
Current Drug Therapy Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury
Endocrine, Metabolic & Immune Disorders - Drug Targets